Proliferation Markers and Cell Cycle Inhibitors in Pituitary Adenomas

2004 ◽  
pp. 110-126 ◽  
Author(s):  
W. Saeger
Keyword(s):  
Cell Cycle ◽  
Pituitary Adenomas ◽  
Proliferation Markers ◽  
Cell Cycle Inhibitors

PTTG has a Dual Role of Promotion-Inhibition in the Development of Pituitary Adenomas

2019 ◽  
Vol 26 (11) ◽  
pp. 800-818
Author(s):  
Zujian Xiong ◽  
Xuejun Li ◽  
Qi Yang
Keyword(s):  
Cell Cycle ◽  
Pituitary Adenoma ◽  
Pituitary Adenomas ◽  
Cell Cycle Progression ◽  
Key Factors ◽  
Cycle Progression ◽  
Sister Chromatids ◽  
Regulation Of Cell Cycle ◽  
Late Stages

Pituitary Tumor Transforming Gene (PTTG) of human is known as a checkpoint gene in the middle and late stages of mitosis, and is also a proto-oncogene that promotes cell cycle progression. In the nucleus, PTTG works as securin in controlling the mid-term segregation of sister chromatids. Overexpression of PTTG, entering the nucleus with the help of PBF in pituitary adenomas, participates in the regulation of cell cycle, interferes with DNA repair, induces genetic instability, transactivates FGF-2 and VEGF and promotes angiogenesis and tumor invasion. Simultaneously, overexpression of PTTG induces tumor cell senescence through the DNA damage pathway, making pituitary adenoma possessing the potential self-limiting ability. To elucidate the mechanism of PTTG in the regulation of pituitary adenomas, we focus on both the positive and negative function of PTTG and find out key factors interacted with PTTG in pituitary adenomas. Furthermore, we discuss other possible mechanisms correlate with PTTG in pituitary adenoma initiation and development and the potential value of PTTG in clinical treatment.

Evaluation of NovelN-(piperidine-4-yl)benzamide Derivatives as Potential Cell Cycle Inhibitors in HepG2 Cells

2014 ◽  
Vol 86 (2) ◽  
pp. 223-231 ◽  
Author(s):  
Jin Hou ◽  
Wei Zhao ◽  
Zhi-Ning Huang ◽  
Shao-Mei Yang ◽  
Li-Juan Wang ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Hepg2 Cells ◽  
Cell Cycle Inhibitors ◽  
Benzamide Derivatives

scholarly journals miR-26a Plays an Important Role in Cell Cycle Regulation in ACTH-Secreting Pituitary Adenomas by Modulating Protein Kinase Cδ

Endocrinology ◽  
2013 ◽  
Vol 154 (5) ◽  
pp. 1690-1700 ◽  
Author(s):  
Erica Gentilin ◽  
Federico Tagliati ◽  
Carlo Filieri ◽  
Daniela Molè ◽  
Mariella Minoia ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Pituitary Adenoma ◽  
Protein Kinase ◽  
Pituitary Adenomas ◽  
Viable Cell Number ◽  
Pituitary Cells ◽  
Human Pituitary ◽  
Human Pituitary Adenoma ◽  
Acth Secreting ◽  
Protein Kinase Cδ

Abstract The functional aftermath of microRNA (miRNA) dysregulation in ACTH-secreting pituitary adenomas has not been demonstrated. miRNAs represent diagnostic and prognostic biomarkers as well as putative therapeutic targets; their investigation may shed light on the mechanisms that underpin pituitary adenoma development and progression. Drugs interacting with such pathways may help in achieving disease control also in the settings of ACTH-secreting pituitary adenomas. We investigated the expression of 10 miRNAs among those that were found as most dysregulated in human pituitary adenoma tissues in the settings of a murine ACTH-secreting pituitary adenoma cell line, AtT20/D16v-F2. The selected miRNAs to be submitted to further investigation in AtT20/D16v-F2 cells represent an expression panel including 5 up-regulated and 5 down-regulated miRNAs. Among these, we selected the most dysregulated mouse miRNA and searched for miRNA targets and their biological function. We found that AtT20/D16v-F2 cells have a specific miRNA expression profile and that miR-26a is the most dysregulated miRNA. The latter is overexpressed in human pituitary adenomas and can control viable cell number in the in vitro model without involving caspase 3/7-mediated apoptosis. We demonstrated that protein kinase Cδ (PRKCD) is a direct target of miR-26a and that miR26a inhibition delays the cell cycle in G1 phase. This effect involves down-regulation of cyclin E and cyclin A expression via PRKCD modulation. miR-26a and related pathways, such as PRKCD, play an important role in cell cycle control of ACTH pituitary cells, opening new therapeutic possibilities for the treatment of persistent/recurrent Cushing's disease.

scholarly journals Development of Cell Cycle Inhibitors for Cancer Therapy

2009 ◽  
Vol 16 (2) ◽  
Author(s):  
Gary K. Schwartz ◽  
Mark Dickson
Keyword(s):  
Cell Cycle ◽  
Cancer Therapy ◽  
Cell Cycle Inhibitors

scholarly journals Effects of Cell Cycle Inhibitors on Tau Phosphorylation in N2aTau3R Cells

2008 ◽  
Vol 35 (2) ◽  
pp. 143-150 ◽  
Author(s):  
Concepcion Conejero-Goldberg ◽  
Kirk Townsend ◽  
Peter Davies
Keyword(s):  
Cell Cycle ◽  
Tau Phosphorylation ◽  
Cell Cycle Inhibitors

Future Therapy for HBV: Role of Cell Cycle Inhibitors

2016 ◽  
Vol 15 (4) ◽  
pp. 245-251 ◽  
Author(s):  
Mayur Brahmania ◽  
Harry L. A. Janssen
Keyword(s):  
Cell Cycle ◽  
Cell Cycle Inhibitors ◽  
Future Therapy

Cell Cycle and Cell Proliferation Markers

1996 ◽  
pp. 91-101
Author(s):  
Harry A. Crissman ◽  
Anthony J. Nastasi
Keyword(s):  
Cell Cycle ◽  
Cell Proliferation ◽  
Proliferation Markers
Sign in / Sign up

Export Citation Format

Share Document